The increasing prevalence of chronic illnesses has spurred innovation in the generic injectables sector. This rise in innovation is largely due to a growing preference for intravenous (IV) and intramuscular (IM) delivery methods, which offer rapid therapeutic options. Moreover, generic injectables are gaining wider acceptance as more cost-effective alternatives to branded medications. These factors contribute to the rising market acceptance of generic injectables.